PMID- 36377039
OWN - NLM
STAT- MEDLINE
DCOM- 20230104
LR  - 20230303
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Jan
TI  - Clinical significance of interstitial lung abnormalities and immune checkpoint 
      inhibitor-induced interstitial lung disease in patients with non-small cell lung 
      cancer.
PG  - 73-80
LID - 10.1111/1759-7714.14718 [doi]
AB  - BACKGROUND: Interstitial lung abnormalities (ILAs) are known to be a risk of 
      drug-induced pneumonitis. However, there are few reports on the relationship 
      between ILAs and immune checkpoint inhibitor-related interstitial lung disease 
      (ICI-ILD). We retrospectively investigated the clinical significance of ILAs in 
      patients with non-small cell lung cancer (NSCLC) receiving ICIs. METHODS: We 
      defined ILAs as nondependent abnormalities affecting more than 5% of any lung 
      zone, including ground-glass or diffuse centrilobular nodularities, traction 
      bronchiectasis, honeycombing, and nonemphysematous cysts. Early-onset ICI-ILD was 
      defined as developing within 3 months after the initiation of ICI administration. 
      RESULTS: Of 264 patients with advanced NSCLC, 57 patients (21.6%) had ILAs (43 
      fibrotic and 14 nonfibrotic ILAs). The difference between the incidence of 
      ICI-ILD in patients with or without ILAs was not significant. Of 193 patients 
      treated by ICI monotherapy, 18 (9.3%) developed early-onset ICI-ILD. Among 
      patients receiving ICI monotherapy, the incidence of early-onset ICI-ILD was 
      significantly higher in patients with than in patients without nonfibrotic ILAs. 
      CONCLUSION: The presence of nonfibrotic ILAs is a significant risk for 
      early-onset ICI-ILD in patients with NSCLC undergoing ICI monotherapy. Clinicians 
      should be aware of ILAs, especially nonfibrotic ILAs, before administering ICIs 
      to lung cancer patients.
CI  - (c) 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Murata, Daiki
AU  - Murata D
AUID- ORCID: 0000-0002-4295-5046
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Azuma, Koichi
AU  - Azuma K
AUID- ORCID: 0000-0001-5040-5856
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Matama, Goushi
AU  - Matama G
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Zaizen, Yoshiaki
AU  - Zaizen Y
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Matsuo, Norikazu
AU  - Matsuo N
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Murotani, Kenta
AU  - Murotani K
AD  - Biostatistics Center, Kurume University School of Medicine, Kurume, Japan.
FAU - Tokito, Takaaki
AU  - Tokito T
AUID- ORCID: 0000-0002-8429-2287
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Hoshino, Tomoaki
AU  - Hoshino T
AD  - Division of Respirology, Neurology, and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221114
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/complications
MH  - *Lung Neoplasms/drug therapy/complications
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Clinical Relevance
MH  - *Lung Diseases, Interstitial/drug therapy
MH  - Lung
MH  - *Cysts/complications
PMC - PMC9807441
OTO - NOTNLM
OT  - ICI-ILD
OT  - ILA
OT  - NSCLC
OT  - PD-1 inhibitor
COIS- KA reports receiving personal fees from AstraZeneca, MSD, Bristol Myers Squibb, 
      Ono Pharmaceutical, Takeda Pharmaceutical, Pfizer and Chugai Pharmaceutical. NM 
      reports receiving personal fees from AstraZeneca, Bristol Myers Squibb, Ono 
      Pharmaceutical and Chugai Pharmaceutical. TT reports receiving personal fees from 
      AstraZeneca, Bristol Myers Squibb, MSD, Novartis and Chugai Pharmaceutical. The 
      remaining authors have no conflicts of interest to disclose.
EDAT- 2022/11/16 06:00
MHDA- 2023/01/05 06:00
PMCR- 2022/11/14
CRDT- 2022/11/15 00:22
PHST- 2022/10/18 00:00 [revised]
PHST- 2022/09/17 00:00 [received]
PHST- 2022/10/20 00:00 [accepted]
PHST- 2022/11/16 06:00 [pubmed]
PHST- 2023/01/05 06:00 [medline]
PHST- 2022/11/15 00:22 [entrez]
PHST- 2022/11/14 00:00 [pmc-release]
AID - TCA14718 [pii]
AID - 10.1111/1759-7714.14718 [doi]
PST - ppublish
SO  - Thorac Cancer. 2023 Jan;14(1):73-80. doi: 10.1111/1759-7714.14718. Epub 2022 Nov 
      14.